Antibody Conjugate Therapeutics: Challenge and Potential

Antibody conjugates are a diverse class of therapeutics consisting of a cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells. The notion that antibodies directed toward targets on the surface of malignant cells could be used for drug delivery is not new.

  • Antibody-Drug Conjugates Design And Development
  • Bispecific antibody conjugates in therapeutics
  • Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
  • New Developments in Antibody-Drug Conjugates

Related Conference of Antibody Conjugate Therapeutics: Challenge and Potential

November 26-27, 2018

3rd International Conference on Autoimmunity

Dublin, Ireland (Louis Fitzgerald Hotel)
December 05-06, 2018 | Lisbon, Portugal

Global Meet on Immunology, Hematology & Molecular Biology

Holiday Inn Lisbon, Portugal
December 06-07, 2018

Annual Congress on Antibiotics and Antimicrobial Resistance

Amsterdam, Netherlands
February 22-23, 2019

World Congress on Immunity and Immuno Therapies

Dallas, Texas, USA
March 04-05, 2019

10th Molecular Immunology & Immunogenetics Congress

Barcelona, Spain
March 18-19, 2019

11th Global Summit on Immunology and Cell Biology

Sydney, Australia
March 18-19, 2019

13th International Congress on Autoimmunity

Brisbane, Australia
June 13-14, 2019 |

10th European Immunology Conference

Berlin, Germany
July 24-25, 2019

11th World Congress and Expo on Immunology

Vancouver, Canada
October 21-22, 2019

12th Annual Congress on Immunology & Immunogenetics

Rome, Italy
November 22-23, 2019 |

World Conference on Vaccine and Immunology

Dubai, UAE

Antibody Conjugate Therapeutics: Challenge and Potential Conference Speakers

Recommended Sessions

Related Journals

Are you interested in